The pharma industry is increasingly seeking to improve clinical trials in response to spiralling development times and costs, attrition of promising compounds and tightening budgets.
Given their focus on clinical trials contract research organisations (CRO) are at the forefront of this optimisation and Parexel believes its specialists, with expertise in regulations, business and science, can help companies.
To improve access to its experts Parexel has set up The Expert Office. This consists of specialists, many of whom are former regulators, pharma executives and leaders of medical institutes, who can tackle a range of issues which impact on clinical trials.
Parexel’s team has experience in Phase I to IV and can help with study design, safety, patient recruitment, pricing, reimbursement, compliance and approval.
Specific examples of their work include creation of development plans for successful marketing authorisations and launch and protocol reviews to identify areas that may delay drug development.
This spans therapeutic areas including oncology, cardiology, neurology, rheumatology and infectious diseases and Parexel believes the breadth and quality of its offering will be attractive to clients.
“Customers are increasingly looking to Parexel to provide insightful strategic guidance related to their compounds in development,” explained Udo Kiessling, head of The Expert Office.
“This consolidation of knowledge throughout the lifecycle of a program is focused on helping biopharmaceutical companies make faster, better informed development and commercialization decisions and accelerate clinical research,” added Kiessling.